



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health/ NCI  
9609 Medical Center Drive, Suite 530  
Rockville, MD 20852  
Office (240) 276-5530  
Facsimile (240) 276-5504

September 26, 2019

Kathryn Ardizzone, Esq.  
Knowledge Ecology International  
1621 Connecticut Avenue, Suite 500  
Washington, DC 20009  
+1.202.332.2670  
kathryn.ardizzone@keionline.org

**Subject:** Comments Submitted in Response to Federal Register Notice 2019-18648 (84 FR 45503), entitled  
“Prospective Grant of an Exclusive Patent License: Genetically-Modified Lymphocytes for Cancer  
Therapy”

Dear Ms. Ardizzone:

Thank you for providing us with your comments regarding the above-referenced notice (“Notice”). As you indicated your comments were submitted on behalf of several organizations and individuals, we kindly request that you share our response with these same parties.

Prior to posting the Notice, the NCI determined that the prospective licensee was qualified, both technically and financially, to be granted an exclusive license to the Government’s intellectual property in the specified fields of use. 37 C.F.R. § 404.7(a)(1)(i) provides an opportunity for public comment and possible objection to the proposed license.

NCI considered all written objections timely received in response to the Notice and has since determined that the requirements specified in 37 C.F.R. § 404.7(a)(1)(ii)(A-C) and 37 C.F.R. § 404.7(a)(1)(iii) have been satisfied.

Sincerely,

A handwritten signature in black ink that reads "Andrew Burke".

Andrew Burke, Ph.D.  
Senior Technology Transfer Manager